- Home
- OSRH vs MGX Comparison
OSRH vs MGX Comparison
Compare OSRH & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSRH
- MGX
- Stock Information
- Founded
- OSRH N/A
- MGX 2018
- Country
- OSRH United States
- MGX United States
- Employees
- OSRH N/A
- MGX N/A
- Industry
- OSRH
- MGX
- Sector
- OSRH
- MGX
- Exchange
- OSRH Nasdaq
- MGX NYSE
- Market Cap
- OSRH N/A
- MGX 65.0M
- IPO Year
- OSRH N/A
- MGX 2024
- Fundamental
- Price
- OSRH $1.28
- MGX $1.59
- Analyst Decision
- OSRH
- MGX Strong Buy
- Analyst Count
- OSRH 0
- MGX 4
- Target Price
- OSRH N/A
- MGX $14.75
- AVG Volume (30 Days)
- OSRH 100.7K
- MGX 354.0K
- Earning Date
- OSRH 05-24-2025
- MGX 05-16-2025
- Dividend Yield
- OSRH N/A
- MGX N/A
- EPS Growth
- OSRH N/A
- MGX N/A
- EPS
- OSRH N/A
- MGX N/A
- Revenue
- OSRH N/A
- MGX $52,295,000.00
- Revenue This Year
- OSRH N/A
- MGX N/A
- Revenue Next Year
- OSRH N/A
- MGX $6.95
- P/E Ratio
- OSRH N/A
- MGX N/A
- Revenue Growth
- OSRH N/A
- MGX 16.84
- 52 Week Low
- OSRH $1.25
- MGX $1.23
- 52 Week High
- OSRH $13.40
- MGX $8.18
- Technical
- Relative Strength Index (RSI)
- OSRH N/A
- MGX 49.06
- Support Level
- OSRH N/A
- MGX $1.41
- Resistance Level
- OSRH N/A
- MGX $1.64
- Average True Range (ATR)
- OSRH 0.00
- MGX 0.15
- MACD
- OSRH 0.00
- MGX -0.00
- Stochastic Oscillator
- OSRH 0.00
- MGX 45.24
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.